Document is current
Any future updates will be listed below
-
Authors
Mateo, Joaquin
McKay, Rana
Abida, Wassim
Aggarwal, Rahul http://orcid.org/0000-0001-7003-7982
Alumkal, Joshi
Alva, Ajjai
Feng, Felix http://orcid.org/0000-0002-0963-7687
Gao, Xin
Graff, Julie
Hussain, Maha
Karzai, Fatima http://orcid.org/0000-0002-3244-1332
Montgomery, Bruce
Oh, William http://orcid.org/0000-0001-5113-8147
Patel, Vaibhav
Rathkopf, Dana
Rettig, Matthew
Schultz, Nikolaus
Smith, Matthew
Solit, David http://orcid.org/0000-0002-6614-802X
Sternberg, Cora
Van Allen, Eliezer http://orcid.org/0000-0002-0201-4444
VanderWeele, David
Vinson, Jake
Soule, Howard R.
Chinnaiyan, Arul http://orcid.org/0000-0001-8743-7480
Small, Eric http://orcid.org/0000-0003-3191-6268
Simons, Jonathan W.
Dahut, William
Miyahira, Andrea K.
Beltran, Himisha http://orcid.org/0000-0003-3259-2226
-
License Information
Text and Data Mining valid from 2020-11-01
Version of Record valid from 2020-11-01
-
More Information
Article History
Received: 7 December 2019
Accepted: 9 October 2020
First Online: 17 November 2020
Competing interests
: J.M. reports advisory board participation for Amgen, AstraZeneca, Roche, Janssen, MSD and Clovis Oncology; and research funding from AstraZeneca and Pfizer Oncology. R.M. received research funding from Bayer, Pfizer and Tempus; serves on advisory board for Bayer, Bristol Myers Squib, Exelixis, Janssen, Novartis, Pfizer, Sanofi and Tempus; and is a consultant for Dendreon and Vividion. W.A. reports consulting/advisory for Clovis, Janssen, More Health, ORIC and Daiichi Sankyo; research funding from AstraZeneca, Zenith Epigenetics, Clovis, GlaxoSmithKline, ORIC and Epizyme; travel from GlaxoSmithKline, Clovis and ORIC; and honoraria from CARET. R.A. reports advisory board participation and research funding from Merck, AstraZeneca and Janssen. B.M. reports research funding from AstraZeneca, Janssen, Clovis, Astellas and Beigene. M.R. reports consulting for Amgen, Ambryx and Constellation; educational writing and consulting for Plexus; speaking for Bayer and Janssen; and funding and clinical research support from Novartis, Astellas, Medivation and Merck. D.S. has consulted for/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, BioBridge, Vivideon Therapeutics and Illumina. E.V.A. reports advisory/consulting from Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio and Monte Rosa; research support from Novartis and BMS; equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft and Monte Rosa; travel reimbursement from Roche/Genentech; and institutional patents on chromatin mutations and immunotherapy response, and methods for clinical interpretation. D.V. reports honoraria from Clovis Oncology. H.B. reports advisory/consulting from Janssen, Amgen, Astra Zeneca, Pfizer, Astellas and Sanofi Genzyme; and research funding from Janssen, Abbvie Stemcentryx, Eli Lilly, Millenium and Astellas. J.V. is employed by the Prostate Cancer Clinical Trials Consortium. H.R.S., J.W.S. and A.K.M. are employed by the Prostate Cancer Foundation.
